Search Results

There are 7711 results for: content related to: Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

  1. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Article first published online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  2. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Article first published online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  3. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Article first published online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  4. You have free access to this content
    Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 242–252, Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA and THE JAPANESE USTEKINUMAB STUDY GROUP

    Article first published online : 29 SEP 2011, DOI: 10.1111/j.1346-8138.2011.01347.x

  5. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 7, July 2011, Pages: 851–857, L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne and H.L. Sofen

    Article first published online : 27 APR 2011, DOI: 10.1111/j.1468-3083.2011.04082.x

  6. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    L. Puig, A. López, E. Vilarrasa and I. García

    Article first published online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  7. Novel biologic therapies in development targeting IL-12/IL-23

    Journal of the European Academy of Dermatology and Venereology

    Volume 24, Issue s6, October 2010, Pages: 5–9, PCM Van De Kerkhof

    Article first published online : 9 SEP 2010, DOI: 10.1111/j.1468-3083.2010.03830.x

  8. Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 257–267, Dr Honghui Zhou, Dr Chuanpu Hu, Dr Yaowei Zhu, Dr Ming Lu, Dr Sam Liao, Dr Newman Yeilding and Dr Hugh M. Davis

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009343695

  9. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 162–175, Dr Yaowei Zhu, Dr Chuanpu Hu, Dr Ming Lu, Dr Sam Liao, Dr Joseph C. Marini, Dr Jennifer Yohrling, Dr Newman Yeilding, Dr Hugh M. Davis and Dr Honghui Zhou

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008329556

  10. Comparing biological therapies in psoriasis: implications for clinical practice

    Journal of the European Academy of Dermatology and Venereology

    Volume 24, Issue s6, October 2010, Pages: 10–14, CEM Griffiths

    Article first published online : 9 SEP 2010, DOI: 10.1111/j.1468-3083.2010.03831.x

  11. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 9, September 2011, Pages: 1037–1040, A. Clemmensen, M. Spon, L. Skov, C. Zachariae and R. Gniadecki

    Article first published online : 25 NOV 2010, DOI: 10.1111/j.1468-3083.2010.03914.x

  12. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 89, Issue 5, October 2010, Pages: 351–363, Pauline L. Martin, Clifford Sachs, Noritaka Imai, Hideshi Tsusaki, Satoru Oneda, Qun Jiao and George Treacy

    Article first published online : 10 JUN 2010, DOI: 10.1002/bdrb.20250

  13. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue s5, August 2012, Pages: 2–8, Christopher E.M. Griffiths and Giampiero Girolomoni

    Article first published online : 3 JUL 2012, DOI: 10.1111/j.1468-3083.2012.04604.x

  14. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Article first published online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  15. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 6, June 2012, Pages: 768–777, C. Ferrándiz, A. García, A.J. Blasco and P. Lázaro

    Article first published online : 30 NOV 2011, DOI: 10.1111/j.1468-3083.2011.04357.x

  16. You have free access to this content
    Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

    British Journal of Pharmacology

    Volume 160, Issue 4, June 2010, Pages: 810–820, Wolfgang Weger

    Article first published online : 1 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00702.x

  17. You have free access to this content
    The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 1145–1152, T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi, on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups

    Article first published online : 29 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11142.x

  18. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

    British Journal of Dermatology

    Volume 162, Issue 1, January 2010, Pages: 137–146, M. Lebwohl, K. Papp, C. Han, B. Schenkel, N. Yeilding, Y. Wang and G.G. Krueger

    Article first published online : 9 NOV 2009, DOI: 10.1111/j.1365-2133.2009.09491.x

  19. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

    British Journal of Dermatology

    Volume 168, Issue 5, May 2013, Pages: 990–998, E.M. Baerveldt, A.J. Onderdijk, D. Kurek, M. Kant, E.F. Florencia, A.S. Ijpma, P.J. van der Spek, J. Bastiaans, P.A. Jansen, J.W.J. van Kilsdonk, J.D. Laman and E.P. Prens

    Article first published online : 25 APR 2013, DOI: 10.1111/bjd.12175

  20. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

    The Journal of Dermatology

    Volume 39, Issue 9, September 2012, Pages: 761–769, Hidemi NAKAGAWA, Brad SCHENKEL, Mai KATO, Takeshi KATO, Atsuyuki IGARASHI and The Japanese Ustekinumab Study Group

    Article first published online : 12 MAR 2012, DOI: 10.1111/j.1346-8138.2012.01521.x